SHALBY Shalby Q3 FY26 results (Oct–Dec 2025) and concall
Shalby Limited reported a mixed Q3 FY26, with consolidated revenue marginally declining by 0.6% YoY to INR 279.4 crores, primarily due to softness in the standalone hospital business. However, the MedTech segment demonstrated strong growth, with consolidated revenue up 29% YoY and EBITDA turning positive. The hospital business faced challenges from insurance contract renegotiations and doctor attrition, but management expects a rebound with new doctor hirings, technology investments, and resolution of insurance issues, alongside a planned reduction in effective tax rate.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 1.4%, net profit up 133.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 268 | 276 | 265 | 296 | 285 +6% | 272 −1% |
| EBITDA | 33 | 34 | 21 | 42 | 42 +27% | 30 −12% |
| Net profit | 2 | -3 | -12 | 8 | 7 +250% | 1 +133% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
